These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 19380447

  • 1. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.
    Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA.
    J Clin Oncol; 2009 Jun 10; 27(17):2838-47. PubMed ID: 19380447
    [Abstract] [Full Text] [Related]

  • 2. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
    Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.
    Lung Cancer; 2012 Jun 10; 76(3):478-85. PubMed ID: 22277104
    [Abstract] [Full Text] [Related]

  • 3. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials.
    Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG.
    J Clin Oncol; 2005 Oct 01; 23(28):6941-8. PubMed ID: 16192582
    [Abstract] [Full Text] [Related]

  • 4. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
    Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P, Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group.
    Circulation; 2008 Jan 29; 117(4):526-35. PubMed ID: 18195176
    [Abstract] [Full Text] [Related]

  • 5. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep 29; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.
    Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF.
    J Clin Oncol; 2008 May 10; 26(14):2342-9. PubMed ID: 18467726
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy-induced anemia: the story of darbepoetin alfa.
    Vansteenkiste J, Wauters I, Elliott S, Glaspy J, Hedenus M.
    Curr Med Res Opin; 2013 Apr 10; 29(4):325-37. PubMed ID: 23323876
    [Abstract] [Full Text] [Related]

  • 8. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
    Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA, Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators.
    N Engl J Med; 2010 Sep 16; 363(12):1146-55. PubMed ID: 20843249
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
    Gordon D, Nichols G, Ben-Jacob A, Tomita D, Lillie T, Miller C.
    Oncologist; 2008 Jun 16; 13(6):715-24. PubMed ID: 18586927
    [Abstract] [Full Text] [Related]

  • 11. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 16; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun 16; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
    Wauters I, Vansteenkiste J.
    Expert Rev Anticancer Ther; 2012 Nov 16; 12(11):1383-90. PubMed ID: 23113603
    [Abstract] [Full Text] [Related]

  • 15. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Smith RE, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA.
    J Clin Oncol; 2008 Mar 01; 26(7):1040-50. PubMed ID: 18227526
    [Abstract] [Full Text] [Related]

  • 16. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-Douglas NW, Singh AK, Toto R, Uno H, Ivanovich P.
    Am J Kidney Dis; 2013 Feb 01; 61(2):238-46. PubMed ID: 23159232
    [Abstract] [Full Text] [Related]

  • 17. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.
    Vansteenkiste J, Poulsen E, Rossi G, Glaspy J.
    Oncology (Williston Park); 2002 Oct 01; 16(10 Suppl 11):45-55. PubMed ID: 12435173
    [Abstract] [Full Text] [Related]

  • 18. The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure.
    Klapholz M, Abraham WT, Ghali JK, Ponikowski P, Anker SD, Knusel B, Sun Y, Wasserman SM, van Veldhuisen DJ.
    Eur J Heart Fail; 2009 Nov 01; 11(11):1071-7. PubMed ID: 19815661
    [Abstract] [Full Text] [Related]

  • 19. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
    Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR, American Society of Clinical Oncology, American Society of Hematology.
    J Clin Oncol; 2010 Nov 20; 28(33):4996-5010. PubMed ID: 20975064
    [Abstract] [Full Text] [Related]

  • 20. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
    Prescrire Int; 2005 Oct 20; 14(79):174-6. PubMed ID: 16285072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.